Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 62.66% ano a ano.
Subavaliada
O PE mais recente da empresa é -66.85, em uma faixa percentil baixa de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 151.51M ações, uma redução de 8.01% em relação ao trimestre anterior.
Mantido por Andreas Halvorsen
O Super Investidor Andreas Halvorsen possui 30.08M ações desta empresa.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 0.99.